Evaluation of Eltrombopag Efficacy in Patients with Hepatitis C-induced Thrombocytopenia: Systematic Reviews of Meta-Analysis

Abstract

Thrombocytopenia is a popular hematological disorder seen in infected patients
having the hepatitis C virus (HCV). Eltrombopag was approved to be used in
thrombocytopenia associated with HCV. The aim of our meta-analysis is to produce
evidence about the efficacy and safety drug of Eltrombopag in the prevention and
treatment Thrombocytopenia caused by HCV-associated cirrhosis. We searched for
computer literature from Cochrane Central, Elsevier, Springer and PubMed. For
qualifying research, records were screened, and data was collected and synthesized
by using Windows Review Manager 5.3. Result: Three randomized controlled trials
(N = 1886 patients) in the final analysis were included. The overall effect estimate
favored the Eltrombopag group (RR = 2.37; 95% CI [1.28, 4.37] P = 0.006), pooled
studies showed significant heterogeneity (I2 = 85%; P = 0.0002). The pooled RR for
adverse effects was as follows: severe adverse effects (RR = 1.30; 95% CI [1.10-
1.52]; P =0.001); headache (RR = 1.10; 95% CI [0.89, 1.35]; P = 0.37), diarrhea (RR